

BUILDING INNOVATION IN DRUG DISCOVERY

DEVELOPING CUTTING-EDGE
TECHNOLOGIES THROUGH
INDUSTRY-ACADEMIA
COLLABORATION



QUICK FACTS

EU-OPENSREEN IS A NON-PROFIT EUROPEAN RESEARCH INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY AND EARLY DRUG DISCOVERY.

Our mission is to support researchers in developing chemical tool compounds for basic and applied research through an integrated academic network of state-of-the-art screening platforms and medicinal chemistry groups.

- Founded March 2018
- 8 member countries and 1 observer country with 37 partner sites
- Central office in Berlin
- 22 assay development and screening sites
- 11 medicinal chemistry sites
- 3 chemoproteomics and spatial MS-based omics sites
- 1 database host (ECBD)



OPPORTUNITIES FOR INDUSTRY

Innovation is the central goal of EU-OPENSREEN. We promote collaboration between academia and industry to create technological excellence, thereby stimulating economic development and social progress.

PROVIDING ACCESS TO EXPERTISE, EQUIPMENT AND RESOURCES

- Drug development support from hit identification to lead optimization
- Open access compound libraries: the European Chemical Biology Library ([ECBL](#)), the Academic Compound Library ([EACL](#)) and the Fragment Library ([FBLD](#)).
- Open access European Chemical Biology Database ([ECBD](#)) containing structures, physicochemical and biological data.
- Training platforms for cutting-edge drug discovery technologies.

FOSTERING ACADEMIA - INDUSTRY COLLABORATION

- Act as European open innovation partner in drug discovery for the pharma and biotech sector using a pre-competitive model.
- Promote collaboration with industry by connecting public and private interests through our industry boards.

SUPPORTING NETWORKS

- Networking is at the heart of innovative business. Our European consortium has the unique opportunity to bring people together and promote innovation and knowledge sharing.
- Considering your scientific focus and business interest we will help you to find your best R&D partner.

EU-OPENSREEN INDUSTRY BOARDS

THE INDUSTRY LIAISON OFFICE (ILO)

acts as primary communication channel between industry representatives and EU-OPENSREEN partner sites to identify new collaborative opportunities.

THE INDUSTRY ASSOCIATE GROUP (IAG)

supports the establishment of access rules and IP regulations between EU-OPENSREEN and industrial partners.

Industry partners of ILO and IAG



HOW TO COLLABORATE WITH US

EU-OPENSREEN will work in close collaboration with you to ensure effective communication and efficient project development with our partners.

We offer you the following attractive collaborative models



Early drug discovery for SMEs offers services of EU-OPENSREEN including assay development, screening and hit optimization towards new lead compounds.



Co-developments with reagent/instrumentation providers focused on validating novel technologies by screening EU-OPENSREEN compound libraries.

SUCCESSFUL COLLABORATIONS

NANOBRET FOR INTRACELLULAR KINASE ACTIVITY AND TARGET ENGAGEMENT

Automation of novel NanoBRET assays for measuring the activity of the EU-OPENSOURCE European Chemical Biology Library on different biological targets.

Industry Partner:



EU-OPENSOURCE Partners:




We are very pleased with the EU-OPENSOURCE ERIC collaboration. The two co-development studies undertaken in Spain revealed a wealth of information about applications of our NanoBRET Intracellular Kinase Target Engagement system on new screening platforms. The insights we gained will help us to further validate and expand our assay capabilities.

Promega Cooperation

HIGH-THROUGHPUT MAPPING OF BIOACTIVES WITH THE PERMEAPAD® PLATE

Evaluation of cell permeability of bioactive compounds of the ECBD library with a novel membrane technology.

Industry Partners:



EU-OPENSREEN Partners:



DROPLET MICROARRAY TECHNOLOGY APPLIED TO CELL PAINTING

Extending the scope of droplet microarray technology towards miniaturization of cell painting assay.

Industry Partner:




EU-OPENSREEN Partner:



DEVELOPMENT OF NOVEL CETSA APPROACHES FOR EVALUATING LIGAND BINDING IN CELL LYSATES, LIVING CELLS AND TISSUES

Evaluation of target engagement and compound-target interaction in cells by using CETSA technology focusing on nucleotide-metabolizing enzymes.

Industry Partner:



EU-OPENSREEN Partners:



EU-OPENSOURCE

WILL FOSTER YOUR
COLLABORATION WITH
ADVANCED EUROPEAN
CHEMICAL BIOLOGY
PLATFORMS TO
STRENGTHEN DRUG
DISCOVERY IN EUROPE
AND BEYOND.

INDUSTRY COLLABORATION CONTACT

**EU-OPENSOURCE****Central Office**

Dr. Robert Harmel
industry@eu-openscreen.eu
Phone: +49 (0)30 9489 2400

**Partner Site****University of Oslo (UiO)**

Dr. Kjetil Taskén
kjetil.tasken@medisin.uio.no
Phone: +47 908 60 759

**Partner Site****University of Santiago de Compostela (USC)**

Dr. Mabel Loza
mabel.loza@usc.es
Phone: +34 8818 15460

STAY INFORMED

Subscribe to our newsletter and receive latest news and up-dates

[Sign up here](#)



IMPRINT

PUBLISHER

EU-OPENSREEN ERIC
Robert-Rössle-Str. 10
13125 Berlin, Germany
Phone: +49 (0)30 9489 2400
www.eu-openscreen.eu

LAYOUT/DESIGN

KLIMEK WEB/PRINT/BRAND,
www.h-klimek.de

EU-OPENSREEN OFFICE

Robert-Rössle-Str. 10
13125 Berlin, Germany
+49 (0)30 9489 2400
office@eu-openscreen.eu

COMMUNICATION



@EuOpenscreen



@EU-OPENSREEN



@euopenscreen



@eu_openscreen

EUROPEAN PROJECT FUNDING



This project receives funding from the European Union's Horizon 2020 research and innovation programme under grant agreement:

No 101132028 (EU-OPENSREEN IMPULSE)

IF YOU WANT
TO GO FAST, GO
ALONE.

IF YOU WANT
TO GO FAR, GO
TOGETHER!

www.eu-openscreen.eu